Survodutide vs Tirzepatide
A glucagon dual agonist vs the approved GIP dual
Survodutide (Boehringer Ingelheim) adds glucagon receptor agonism to GLP-1, with standout liver-disease data; tirzepatide (Mounjaro/Zepbound) is the approved GLP-1/GIP dual you can use today. Here is how the investigational glucagon route compares with the proven incretin standard.
Glucagon vs GIP: two ways to extend GLP-1
Both drugs start from GLP-1 and add a second receptor. Survodutide adds glucagon receptor agonism, which raises energy expenditure and drives hepatic fat oxidation — the reason its strongest signal so far is in metabolic liver disease (MASH). Tirzepatide instead adds GIP, which enhances appetite suppression and the metabolic response and underpins its large, well-proven weight loss.
In a Phase 2 obesity trial, survodutide produced about 19% mean weight loss at 46 weeks, and a Phase 2 MASH trial showed meaningful improvement in liver inflammation and fibrosis. Tirzepatide reported roughly 22.5% weight loss in SURMOUNT-1 and has its own positive MASH data.
The key practical difference is stage: tirzepatide is FDA approved and available now, while survodutide is investigational and in Phase 3. Cross-trial percentages are not directly comparable.
Survodutide vs Tirzepatide at a glance
- ⚡Mechanism: GLP-1 + glucagon dual agonist
- ⚡Phase 2 obesity: about 19% mean weight loss at 46 weeks
- ⚡Standout Phase 2 data in MASH (liver inflammation + fibrosis)
- ⚡Glucagon raises energy expenditure and reduces liver fat
- ⚡Status: investigational — Phase 3 ongoing, not FDA approved
- ✓Mechanism: GLP-1 + GIP dual agonist
- ✓SURMOUNT-1: about 22.5% mean weight loss at 72 weeks
- ✓Also has positive MASH trial data
- ✓Once-weekly subcutaneous pen, no mixing
- ✓FDA approved for obesity and type 2 diabetes — available now
Which mechanism matters for you?
If liver disease is your central concern, survodutide’s glucagon mechanism and its MASH data make it one of the most-watched candidates — but it is not yet approved, so it is a "watch and discuss with a hepatologist" option rather than something you can start. Tirzepatide also has MASH evidence and the advantage of being available today.
For straightforward weight management with proven, approved data and a simple pen, tirzepatide is the practical choice now. Survodutide becomes relevant if and when its Phase 3 obesity and liver programs confirm the early signals and it reaches the market.
Track now, compare later
There is no head-to-head trial of survodutide and tirzepatide, so the numbers here come from separate studies and are only directional. Logging your own response in Shotlee — weight, appetite, side effects, and especially liver-related labs if relevant — gives you an objective baseline that makes any future switch evidence-based.
Use this comparison as a starting framework and confirm specifics with your healthcare provider, particularly given survodutide’s liver focus.
Survodutide vs Tirzepatide: Frequently Asked Questions
Not proven — there is no head-to-head trial. Tirzepatide has deeper, approved weight-loss data (about 22.5%), while survodutide’s distinctive strength is its glucagon mechanism and Phase 2 MASH/liver results. Survodutide is still investigational, so cross-trial comparisons are only directional.
Survodutide is a GLP-1/glucagon dual agonist (glucagon adds energy expenditure and liver-fat reduction); tirzepatide is a GLP-1/GIP dual agonist (GIP enhances appetite control). Tirzepatide is FDA approved; survodutide is in Phase 3.
Survodutide’s glucagon mechanism targets liver fat, and a Phase 2 trial showed meaningful improvement in MASH and fibrosis. It is investigational, so it is not yet an approved MASH treatment — decisions should involve a hepatologist.
Survodutide reported about 19% at 46 weeks in a Phase 2 obesity trial; tirzepatide reported about 22.5% at 72 weeks in SURMOUNT-1. These are separate trials of different lengths and are not directly comparable.
Yes. Shotlee logs doses, weight, side effects, and labs for your current protocol, free — ready to compare if you change medications.
Track Your Protocol in Shotlee
Free dose logging, weight trends, lab snapshots, and side effect tracking.
